MHRA
MHRA approves first lower-carbon beclometasone inhalers for asthma
July 24, 2026Research and Development MHRA, asthma, inhaler, lower carbon
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first pressurised metered dose inhalers (pMDIs) to use …
MHRA to establish Northern Ireland hub for life sciences sector
May 13, 2026MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) is establishing a new hub in Northern Ireland aimed at strengthening engagement …
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
January 29, 2026Medical Communications MHRA, NHS, NICE, Wellcome, digital technologies, medical communications, mental health
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together with other forms of care, …
IMed Consultancy releases white paper on Digital Mental Health Technologies
October 20, 2025Medical Communications Digital Mental Health Technologies, IMed Consultancy, MHRA
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has published a new white paper …
Dual immunotherapy for bowel cancer now available under NHS
April 23, 2025Research and Development Bristol Myer Squibb, MHRA, NICE, Oncology, bowel cancer, colorectal cancer, immunotherapy
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …
MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients
January 30, 2025Research and Development MHRA, Oncology, approvals, multiple myeloma, rare diseases
The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma …
New gastric & gastro-oesophageal junction cancer treatment VYLOYâ„¢ â–¼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment
April 25, 2024Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism
Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
March 21, 2024Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …
MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
January 31, 2024Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
MHRA approves Mounjaro for diabetes and weight management
January 26, 2024Medical Communications Diabetes, MHRA, Mounjaro, weight management
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …
Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy
January 12, 2024Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera
Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
ViroCell and GOSH gain MHRA manufacturing approval
November 1, 2023Manufacturing and Production Great Ormand Street Hospital, MHRA, Pharmacy, ViroCell, manufacturing, viral vectors
ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art …
AbbVie’s Aquipta receives MHRA marketing authorisation
September 5, 2023Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
Latest content
FibroFind appoints Lee Borthwick as CEO
